JPM23: J&J stayed in the back seat during Horizon bidding war, CEO says

In the recent battle for rare disease expert Horizon, Johnson & Johnson largely stuck to the background, CEO Joaquin Duato explained at this year’s J.P. Morgan Healthcare Conference.